阿托西班临床应用风险管理专家共识  

Expert Consensus on Risk Management in the Clinical Application of Atosiban

作　　者：中国药师协会妇儿专科药师分会 中国妇幼保健协会医疗风险防控专业委员会 杜博冉[2] 冯欣[2] 盖迪 贡磊磊 李轶凡[2] 刘小艳[2] 齐歆[2] 王然[2] 阴赪宏[2] 余馨 张伊 周博雅 The Women’s and Children’s Pharmacists Branch of Chinese Pharmacists Association;The Medical Risk Prevention and Control Professional Committee of China Maternal and Child Health Association

机构地区：[1]不详 [2]首都医科大学附属北京妇产医院 [3]首都医科大学附属北京朝阳医院

出　　处：《中国医院用药评价与分析》2025年第1期1-5,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金青年项目(No.72204170);首都卫生发展专项(No.首发2024-2-2115);北京市医院管理中心临床医学专项经费资助(No.ZYLX202119);北京市属医院科研培育项目(No.PZ2021028);中国药学会医院药学专业委员会医院药学科研专项资助项目(No.CPA-Z05-ZC-2022-002);中华医学会临床药学分会2023年度临床药学青年项目(No.Z-2021-46-2101-2023)。

摘　　要：随着我国生育人群年龄的不断推迟及辅助生殖技术的发展,对于早产保胎治疗的临床需求不断增加,阿托西班在我国治疗早产的临床应用逐年增加。但目前尚缺乏对于阿托西班临床应用风险管理的规范和标准。为进一步提高阿托西班的临床应用管理水平,防范阿托西班临床应用风险,中国药师协会妇儿专科药师分会及中国妇幼保健协会医疗风险防控专业委员会牵头组织专家撰写了《阿托西班临床应用风险管理专家共识》。该共识参考国内外最新研究成果及《早产临床防治指南(2024版)》,针对阿托西班治疗失效、不良反应、成本负担、药品短缺、药物过度使用、超说明书用药的临床风险及管理措施进行阐述,为临床对于阿托西班规范及合理使用提供参考。With postponement of the childbearing age in China and the development of assisted reproductive technology,the clinical demand for the treatment of premature birth has been increasing,and the clinical application of atosiban in China is increasing year by year in China.However,there was still a lack of standards and guidelines for clinical application and risk management of atosiban.In order to further improve the clinical application management level of atosiban and prevent the risk of clinical application,the Women’s and Children’s Pharmacists Branch of Chinese Pharmacists Association and the Medical Risk Prevention and Control Professional Committee of China Maternal and Child Health Association took the lead in organizing experts to formulate Expert Consensus on Risk Management in the Clinical Application of Atosiban.With reference to the latest research results at home and abroad and the Clinical Guidelines for the Prevention and Treatment of Preterm Birth(2024 edition),the consensus analyzes on the clinical risks and management measures for the therapeutic failure of atosiban,adverse drug reactions,cost burden,drug shortages,overuse and off-label drug use,and provides reference for the standardization and rational application of atosiban in the clinic.

关 键 词：阿托西班 风险管理 早产 临床应用 药物安全 

分 类 号：R969.3[医药卫生—药理学] R984[医药卫生—药学]